AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Oct 2018 07:00 AM
RNS
FDA Orphan Drug for Lynparza in pancreatic cancer
01 Oct 2018 03:00 PM
RNS
Total Voting Rights
01 Oct 2018 07:00 AM
RNS
Atacand Agreement with Cheplapharm Completed
28 Sep 2018 04:00 PM
RNS
Previous Announcement Regarding Appointment Of NED
25 Sep 2018 01:15 PM
RNS
Overall survival data for Imfinzi: Stage III NSCLC
24 Sep 2018 04:10 PM
RNS
EMA approves AZ's Imfinzi for Stage III NSCLC
24 Sep 2018 07:00 AM
RNS
Farxiga gets positive result in DECLARE-TIMI 58
14 Sep 2018 07:00 AM
RNS
FDA approves AZ's Lumoxiti in hairy cell leukaemia
07 Sep 2018 07:00 AM
RNS
Tezepelumab FDA Breakthrough Therapy Designation
06 Sep 2018 07:00 AM
RNS
Directorate Change
03 Sep 2018 03:00 PM
RNS
Total Voting Rights
31 Aug 2018 07:00 AM
RNS
AstraZeneca Update on Anifrolumab in SLE
30 Aug 2018 07:00 AM
RNS
EC approves Bydureon BCise device for T2 diabetes
23 Aug 2018 07:00 AM
RNS
AstraZeneca PIIIb trial update for Bevespi in COPD
21 Aug 2018 07:00 AM
RNS
AZ's Tagrisso approved in Japan for 1st-line NSCLC
15 Aug 2018 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2018 07:00 AM
RNS
EMA grants OD for selumetinib in NF1
01 Aug 2018 03:00 PM
RNS
Total Voting Rights
27 Jul 2018 02:00 PM
RNS
CHMP recommends Imfinzi for Stage III nsclc
26 Jul 2018 07:00 AM
RNS
AZN: H1 2018 Results
24 Jul 2018 07:00 AM
RNS
Atacand to be divested to Cheplapharm in Europe
18 Jul 2018 12:00 PM
RNS
Holding(s) in Company
02 Jul 2018 03:00 PM
RNS
Total Voting Rights
02 Jul 2018 07:00 AM
RNS
Imfinzi approved in Japan for Stage III nsclc
02 Jul 2018 07:00 AM
RNS
Lynparza approved in Japan for BRCAm breast cancer
29 Jun 2018 03:00 PM
RNS
Bydureon receives positive CHMP opinion for BCise
28 Jun 2018 01:30 PM
RNS
AZ and Luye Pharma complete agreement for Seroquel
27 Jun 2018 07:00 AM
RNS
Lynparza: significant PFS 1st-line ovarian cancer
26 Jun 2018 07:00 AM
RNS
Board Committee Changes
22 Jun 2018 07:00 AM
RNS
Publication of a Prospectus
12 Jun 2018 07:00 AM
RNS
Update: lanabecestat Phase III Alzheimer's trials
08 Jun 2018 05:30 PM
RNS
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
08 Jun 2018 07:00 AM
RNS
Director Declaration
01 Jun 2018 03:00 PM
RNS
Block listing Interim Review
01 Jun 2018 03:00 PM
RNS
Total Voting Rights
01 Jun 2018 11:00 AM
RNS
Director Declaration
30 May 2018 07:00 AM
RNS
Update on TERRANOVA PIII trial for Fasenra in COPD
25 May 2018 07:00 AM
RNS
AZ's Imfinzi: significant OS in Stage III nsclc
21 May 2018 07:00 AM
RNS
AZ regulatory submission in Japan for Forxiga
21 May 2018 07:00 AM
RNS
US FDA approves Lokelma for adult hyperkalaemia
18 May 2018 05:30 PM
RNS
Result of AGM
18 May 2018 07:00 AM
RNS
AZN: Q1 2018 Results
11 May 2018 07:00 AM
RNS
AstraZeneca update on Fasenra PIII trial in COPD
08 May 2018 11:00 AM
RNS
EMA approves Lynparza: maintenance ovarian cancer
08 May 2018 07:00 AM
RNS
AZ and Luye Pharma enter agreement for Seroquel
04 May 2018 12:00 PM
RNS
Director Declaration
01 May 2018 03:00 PM
RNS
Total Voting Rights
27 Apr 2018 12:30 PM
RNS
AZ: positive CHMP for Tagrisso first-line nsclc
24 Apr 2018 07:00 AM
RNS
AstraZeneca:high level results of the ARCTIC trial
19 Apr 2018 07:00 AM
RNS
FDA approves Tagrisso for 1st-line use in NSCLC

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings